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Background: Recent studies suggested that aquaporins 5 (AQP5) was associated with many kinds of cancers and
regulated many processes of various kinds of cancer cells. Our previous studies also demonstrated that AQP5 was
highly expressed in epithelial ovarian cancer and contributed to the progress of ovarian cancer.
Methods: Lentivirus for knocking-down the expression of AQP5 was prepared and verified by qPCR and Western
blotting. Cell counting kit-8 (CCK8) assay and transwell assay were performed to investigate the role of AQP5 on
proliferation and migration of 3AO cells. The effects of down-regulating AQP5 on tumorigenesis were tested by
tumor xenografts experiments.
Results: An effective lentivirus silencing AQP5 expression was obtained and used in this study. Down-regulating
AQP5 inhibited proliferation and migration of cultured human epithelial ovarian cancer 3AO Cell. Furthermore,
interfering of AQP5 during tumorigenesis could efficiently decrease the tumor growth in athymic mice.
Conclusions: These findings altogether suggest that AQP5 regulated multi processes in ovarian carcinogenesis and
may be an attractive therapeutic target.
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Ovarian cancer is a very serious cancer. It is estimated
that there will be 21,980 ovarian cancer cases newly di-
agnosed and 14,270 deaths due to ovarian cancer among
female in the United States in 2014 which suggested that
ovarian cancer will be the eleventh common cancer and
the fifth common cause of cancer death in women [1].
Early stage ovarian cancer has a good 5 year survival rate
at approx. 92%, although <30% of patients will present
with early stage disease. The majority of ovarian cancers
present at late stage disease (5 year survival 30%) as the
clinical symptoms of ovarian cancer in the early stages
are vague [2,3].Tumor-debulking surgery combined with
following plantinum-taxane combination chemotherapy
has been the fist-line treatment for ovarian cancer for over
twenty year with very high response rate in the initial stage* Correspondence: yjh0121@126.com
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unless otherwise stated.of therapy, while most patients with advanced-stage ovar-
ian cancer relapse within 18 months and finally die from
the disease [4].
Aquaporins (AQPs) are a family of small integral plasma
membrane proteins expressed in all living organisms [5].
AQPs primarily transport water and in some cases, a wide
range of nonpolar solutes such as urea and glycerol and
even some unconventional molecules such as the nonpo-
lar gases carbon dioxide and nitric oxide [6]. In humans,
there are 13 kinds of Aquaporins members divided into
three subgroups as water selective AQPs, aquaglyceropo-
rins and superaquaporins [7]. Aquaporins are found to
mainly function as molecular transporters and involve in
many disease progresses such as various chronic kidney
disease, systemic disease and cancers [7-10]. Recent
studies suggest that Aquaporins could be a promising
drug target [11,12].
The human AQP5 gene encodes a protein of 265 amino
acids containing six transmembrane domain and five con-
necting loops [13]. Previous studies indicated that AQP5. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cells such as corneal epithelium cells, acinar cells in the
lacrimal gland and pulmonary epithelial cells [14]. Overex-
pression of AQP5 have been reported to be associated
with many kinds of cancers such as colorectal, cervical,
lung, breast and epithelial ovarian cancer, and to be a po-
tential prognostic biomarkers [15-19]. The role of AQP5
in carcinogenesis is not yet fully understood. Many studies
demonstrated that overexpression of AQP5 result in the
increase of proliferation, migration and invasion of many
kinds of human cancer cell lines [16,20-23]. Phosphoryl-
ation of AQP5 by protein kinase A (PKA) has been identi-
fied to influence the Ras activity which in turn regulated
the proliferation and transformation of NIH3T3 cells [24].
Besides, the NF-kappaB signaling pathway was also proved
to have a positive correlation with AQP5 expression in
CAOV3 cells [25]. Our previous studies have shown that
the expression of AQP5 in malignant and borderline epi-
thelial ovarian tumors is significantly higher than that in
benign tumors and normal ovarian tissue [26]. The role of
AQP5 in epithelial ovarian tumorigenesis has not previ-
ously been clearly evaluated. Therefore, in this study, we
used lentivirus mediated RNA interference method to
down-regulate the expression to investigate the possible
function of AQP5 in epithelial ovarian cancer cells.
Materials and methods
Animals
The 6–8 weeks old female BALB/c nude mice purchased
from Shanghai Laboratory Animal Center, CAS serves
were used to generate the tumor xenografts model. All
animals were used and cared for following the Animal
Research Advisory Committee of the Shanghai Institute
for Biological Sciences.
Generation of shRNA plasmids
The target sequences against human AQP5 mRNA
(GeneBank ID: NM_001651.3) were designed by Invitro-











shRNA-3#-R 5′-CCTGATCAGCTCCAInvitrogen Corporation. The nucleotide sequences of four
candidates were shown in the Table 1. The oligonucleo-
tides were synthesized by Invitrogen Corporation. The
annealed nucleotides were then ligated into the linearized
pcDNA6.2-GW/EmGFP-miR vector (Invitrogen). All con-
structs were sequenced for verifying.
Cell cultures and transfection
The human epithelial ovarian cancer 3AO cells and hu-
man embryonic kidney (HEK) 293 T cells were obtained
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China) and maintained in Dulbecco modified
Eagle’s medium (DMEM, Gibco) containing 10% fetal bo-
vine serum (FBS, Gibco) and antibiotics at 37°C with 5%
CO2. Plasmids were transfected into HEK293T cells and
3AO cells using Lipofectamine 2000 reagent (Invitrogen)
according the manufacturer’s protocol for virus package
and knock-down efficiency test, respectively.
Reverse-transcription PCR and qPCR
To verify the knock down efficiency of AQP5 shRNA,
3AO cells were treated with Trizol reagent (Invitrogen)
to extract total RNA. RNA was then reverse transcribed
by M-MLV transcriptase (Invitrogen) following the man-
ufacturer’s protocol and amplified using SYBR Ex Taq
premix (Takara, Japan) by iQ5 multicolor real-time PCR
detection system (Bio-Rad). Primers used for qPCR were
as follows: human beta-actin (ACTB) (forward primer:
5′- TCCTTCCTGGGCATGGAGT -3′; reverse primer:
5′- CAGGAGGAGCAATGATCTTGAT -3′); human AQP5
(forward primer: 5′- CTGTCCATTGGCCTGTCTGTC -3′;
reverse primer: 5′- GGCTCATACGTGCCTTTGATG -3′).
Western blotting
Lysates from 3AO cells and tissues were prepared in ice-
cold RIPA buffer (Beyotime) supplied with protease in-
hibitor cocktail (Roche) and 1 mM PMSF (Calbiochem).
After centrifuge at 13,000 × g for 10 min, the supernatant
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(SDS-PAGE) gel. The proteins were separated by elec-
trophoresis, transferred to nitrocellulose membranes
(Millipore), blocked with 5% nonfast milk in Tris buffered
saline (TBS) buffer with 0.05% Tween-20 for 1 hour at
room temperature, and then probed with mouse anti-
AQP5 antibody (1:1300, Abcam, UK) at 4°C overnight.
After incubation for 2 hours with horseradish-peroxidaseFigure 1 Knock-down efficiency of the AQP5 shRNA constructs. (A) Re
scale bar, 50 μm. Levels of AQP5 mRNA (B) and protein (C) in 3AO cells tra
3AO cells infected with indicated lentivirus; scale bar, 50 μm. Expression lev
qPCR (E) and western blotting (F).(HRP)-conjugated rabbit anti-mouse secondary antibody
(1:5000, Santa Cruz Biotechnology, USA), bands were
visualized by ECL plus western blot detection reagent
(GE, USA). The house-keeping gene GAPDH was used
as a loading control and detected by using mouse anti-
GAPDH antibody (1:4000, abmart, China) plus HRP-
conjugated goat anti-mouse secondary antibody (1:5000,
Santa Cruz Biotechnology, USA).presentative images of 3AO cells transfected with indicated plasmids;
nsfected with indicated shRNA contrasts. (D) Representative images of
els of AQP5 of 3AO cells treated with indicated virus determined by
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infection
The most effective AQP5 shRNA tested by qPCR and
western blotting was inserted into plent6.3/V5-Dest
vector (Invitrogen) respectively to generate the shRNA
lentivirus vector by BP recombination following the
standard protocol. The NC control lentivirus vector was
constructed in the same way. The generated plasmids
were confirmed by sequence and then named as Lenti-
AQP5-RNAi and Lenti-NC, respectively. The lentiviral
vectors and packaging vectors were then transfected into
293 T cells. Supernatants containing lentivirus express-
ing AQP5 shRNA or control shRNA were harvested
72 h after transfection and then concentrated by ultra-
centrifugation to purify lentivirus. The titer of lentivirus
was then determined by infected 293 cells. The 3AO
cells were infected with lentivirus at multiplicity of infec-
tion (MOI) of 30 plus 5 ug/ml Polybrene. The knockdown
efficiency of AQP5 by infection was tested by qPCR and
western blotting. Then infected cells were used for CCK8
assay and migration assay.
CCK8 assay
3AO cells infected by AQP5 shRNA lentivirus or control
virus were trypsinized, resuspended. Then 5000 cells
seeded into 96-well plate for each well. Cell viability was
evaluated with Cell Counting Kit-8 (Beyotime) according
to the protocol of the manufacture at daily intervals
from the next day to the sixth day after seeding. After
treated with CCK8 at 37°C for 1 hour, 3AO cells was
used to measure the absorbency at 450 nm using a mi-
croplate reader.
Cell migration assay
The migration ability of 3AO cells infected for 3 days
was determined using a Transwell chamber (Corning).
Briefly, cells were trypsinized and then resuspended byFigure 2 Knocking-down AQP5 decreases 3AO cells proliferation. 3AO
CCK8 assay demonstrated that cells treated with AQP5 shRNA have lower v
three times. Statistic significant differences were observed between cells inDMEM medium without FBS to the concentration of
2 × 106/ml. The transwell plates (8.0 um pore, Corning
Costar) containing 100 ul cell suspension in the upper
chamber and 650 ul DMEM medium with 10% FBS in
the lower chamber was incubated at 37°C in 5% CO2
for 48 h. Then, after removing the cells remaining on
the upper surface of the filter, those cells invaded to the
lower compartment were fixed with Methanol and
stained with crystal violet (GenMed). Cell images were
captured in 3 random fields under light microscope at
4 ×, 10 × and 20 × magnification. In addition, invaded
cells were segregated, lysed and quantified at 570 nm
using spectrophotometer to evaluate the amount of mi-
grated cells.Tumor xenografts
Twenty BALB/c nude mice were divided randomly into
four groups for tumor Xenografts as mock group, PBS
group, Lenti-NC group and Lenti-AQP5-RNAi group.
3AO cells which had been trypsinized and then suspended
with DMEM medium were injected subcutaneously into
the BALB/c nude mice at a dose of 4 × 106/200 ul for the
PBS group, Lenti-NC group and Lenti-AQP5-RNAi group.
200ul DMEM medium without cells were used as a mock
control. After tumors were visible in the groups injected
with cells, tumor length (L) and width (W) were measured
every 3 days and the first day of measurement was marked
as day 0. Tumor volume (V) was determined using the
simplified formula: V = LW2/2. Once the average diameter
of tumors researched approximately 4 to 6 mm, the mice
received an injection with 50 ul solution into the tumor in
multi-position every five days for four times. The PBS buf-
fer, Lenti-NC virus solution and Lenti-AQP5-RNAi virus
solution were used for PBS group and mock group, Lenti-
NC group and Lenti-AQP5-RNAi group, respectively. Tu-
mors were harvested five days after the fourth treatment.cells infected with AQP5 shRNA lentivirus and various controls. The
iability compared with the controls. The experiment was repeated for
fected with AQP5 shRNA virus and NC/mock cells.
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Statistical analysis was performed by Prism 5.0 software.
Data are presented as mean ± SEM. Significance of differ-
ences were determined by unpaired, two-tailed Student’s
t test. P values < 0.05 were considered significant.
Results
AQP5 shRNA effectively knock down AQP5 expression
In order to select the most effective shRNA of AQP5, four
short-hairpin RNA (shRNA) constructs that target human
AQP5 mRNA and a non targeting control shRNA was
transfected into 3AO cells, respectively. Images of trans-
fected cell showed these constructs could be transfected
into 3AO cells with high efficiency (Figure 1A). Both
semiquantitative RT-PCR and western blotting suggestedFigure 3 Knocking-down AQP5 inhibits 3AO cells migration. (A) Repre
100 μm (4 ×), 50 μm (10 ×) and 50 μm (20 ×). (B) Migration ability of 3AO
experiment was performed for three times. Statistic significant differences w
NC/mock cells (t test, p < 0.01).that shRNA-3# was more effective than other shRNAs at
knocking down AQP5 (Figure 1B and C).
The shRNA-3# was then inserted into lentivirus vector
which was used for lentiviral packaging. The concentrated
lentivirus solution was used to infect 3AO cells. Images of
infected cell suggested that 3AO cells could be efficiently
infected by lentivirus (Figure 1D). The knocking down
efficiency of Lenti-AQP5-RNAi lentivirus was proved
by both semiquantitative RT-PCR and western blotting
(Figure 1E and F).
Down-regulation of AQP5 decrease cell proliferation of
3AO cells
Our previous worked demonstrated that the high ex-
pression AQP5 was correlated with epithelial ovariansentative images of 3AO cells with indicated treatments; scale bar,
with different infections was analyzed by transwell assay. The
ere noted between cells infected with AQP5 shRNA virus and
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ovarian tumorigenesis, we firstly examined whether
AQP5 involved in the proliferation of ovarian cancer
cells. Cells infected with lentivirus or without treat-
ment were used to measure the cell viability by CCK8
assay for 6 days. Compared to cells without treatment
or transfected with Lenti-NC virus, cells with low expres-
sion level of AQP5 had a lowed cell proliferation ability
(Figure 2). This initial result suggested that AQP5 played
a potential role in ovarian cell proliferation.
APQ5 is involved in cell migration
To further explore the role of AQP5 in ovarian tumori-
genesis, we used Tanswell assay to investigate whether
AQP5 is associate with migration ovarian cell. The Images
of cells stained with crystal violet suggested that knocking
down the expression of AQP5 resulted in the decrease of
amount of invaded cells (Figure 3A). Additional observa-
tion of absorption assay also proved that the migration
ability of 3AO cell reduced after knocking down the ex-
pression of AQP5 (Figure 3B). All of these data suggested
that AQP5 was involved in the migration of ovarian can-
cer cells.
Reduction expression of AQP5 inhibited tumorigenesis in
tumor xenografts model
To verify the role of AQP5 in tumorigenesis, we performed
xenoplantation in athymic mice with different kinds of
injection in the tumorigenesis process. The growth rate
of tumor size in mice receiving Lenti-AQP5-RNAi virus
started to slow down after virus treatment. While the
tumor in other two treatment groups continued to grow
rapidly. In contrast, mice in the mock group treated withFigure 4 Down-regulating AQP5 expression appears to inhibit tumor
30 days since visible tumor observed. Lentivirus solution or PBS buffer were
researched approximately 4 to 6 mm. No tumor growth was observed in m
deviations of tumor volume were calculated from multiple observations in
between mice received Lenti-AQP5-shRNA virus injection and mice injectePBS buffer though the experiment did not form any
detectable tumor (Figure 4).
Discussion
Our previous studies have identified that the expression
level of AQP5 in malignant and borderline ovarian tumors
is significant higher than those in benign tumors [26]. Our
studies also suggested the probable relationship between
NF-kappaB pathway and AQP5 expression in human ovar-
ian cancer cells [25]. Our present report gave us more in-
sights into the role of AQP5 in the ovarian carcinogenesis
process. It suggested that AQP5 was positively associated
with both proliferation and migration of ovarian cancer
cells, which may also have affected the growth of tumor in
the xenoplantation model. All of these preliminary find-
ings explored the role AQP5 in ovarian cancer and indi-
cated that AQP5 is a putative oncogene and may play
multi roles in ovarian carcinoma.
The literature suggested that AQP5 paly a significant
role in the cancer process and be a potential early bio-
marker for many kinds of tumors [2,18,27,28]. While the
detailed function of AQP5 in cancer is still unclear. Pre-
vious studies proved that deletion of cAMP-protein kin-
ase (PKA) phosphorylation substrate sequence of AQP5
could inhibit the cell proliferative ability of AQP5 in
NIH 3 T3 cells. In addition, the PKA consensus site of
AQP5 was found to be phosphorylated preferentially in
tumors [20]. The following works further demonstrated
that the phosphorylation of AQP5 by PKA activated Ras
activity which regulated proliferation and transformation
of cancer cells [24]. Thus, it is possible that a decrease
of AQP5 lead to the inhibition of Ras activity and then
cell proliferation which could be investigated in our on-
going studies.growth in athymic mice. Tumor growth was observed within
subcutaneously injected when the average diameter of tumors
ice injected with PBS instead of 3AO cells. Means and standard
three groups of mice. Statistically significant differences were noted
d with Lenti-NC virus or PBS buffer (t test, p < 0.01). n = 5 per group.
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migration suggested that AQP5 may determine cell migra-
tion ability by mediating water permeability and regulating
cell shape and volume [29]. Besides, the upregulation of
AQP5 by E2 could increase annexin-2, a regulator of
F-actin remodeling and rearrangement, and result in the
increase of cell migration, invasion and adhesion in
Ishikawa cells [23]. These studies helped us to understand
the role of AQP5 in the cancer cell migration process.
However, more direct and detailed mechanisms are
needed in order to approve the work.
Inhibition of tumor growth by down regulation was
also observed in tumor xenografts model. As injection
of virus with shRNA target AQP5 was performed after
visible tumors were generated, our observation sug-
gested that AQP5 should play an important role in the
ovarian carcinogenesis and be a potential drug target for
ovarian treatment.
Conclusions
In conclusion, this report provides systemic evidence
of the multi role of AQP5 in ovarian tumorigenesis
and indicates that AQP5 is a promising treatment
target beyond a biomarker for ovarian prognosis.
Further investigations on the pathways APQ5 may
involved in are need to understand detailed roles in
tumorigenesis.
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